Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

24-month Prospective, Multicentre, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products in the Prophylactic Treatment of Patients With Haemophilia A (A-SURE)

Next Previous
Trial Profile

24-month Prospective, Multicentre, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products in the Prophylactic Treatment of Patients With Haemophilia A (A-SURE)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efmoroctocog alfa (Primary) ; Factor VIII
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms A-SURE
  • Sponsors Swedish Orphan Biovitrum

    • Most Recent Events

    • 31 Jan 2024 According to a Sobi media release, pooled analysis of real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by age groups data to be presented at EAHAD 2024.
    • 14 Jun 2023 According to Sanofi Media Release, the company will present new scientific data at ISTH 2023, the 31st Congress of the International Society on Thrombosis and Haemostasis.Nine abstracts have been accepted for presentation.
    • 13 Jul 2022 According to a Swedish Orphan Biovitrum media release, results from this trial were presented at the 30th International Society on Thrombosis and Haemostasis (ISTH) Congress, 2022 in London. The results were presented orally by Professor Johannes Oldenburg, the study principal investigator of the study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top